Digital follow-up for safer cancer treatment
Official title: Monitoring of Adverse Events Caused by Systemic Cancer Treatment. Identifying Adverse Events Related to Immunotherapy Treatment Before and After Implementation of Personalized Digital Patient Reported Outcomes
Run by Nordlandssykehuset HF · NCT06476158 · Data updated 2026-11-12
This study tests if a personalized digital follow-up program can help cancer patients on immunotherapy feel safer and healthier compared to regular check-ups.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 900 (estimated) |
| Sponsor | Nordlandssykehuset HF Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Bodø, Nordland) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | June 1, 2025 |
| Study ends | December 31, 2027 |
| Registry record updated | June 26, 2024 |
| Trial ID | NCT06476158 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old with a cancer diagnosis who are receiving immunotherapy as part of their treatment.
✕Probably not a fit
Patients with hematological or gynecological cancers may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the impact of a personalized digital follow-up program on cancer patients receiving immunotherapy. Participants will report their symptoms directly to healthcare personnel through a digital platform, allowing for real-time monitoring of adverse events and overall health. The study compares outcomes between patients using this digital system and those receiving standard follow-up care. The goal is to enhance patient safety, quality of life, and survival rates by improving the detection of treatment-related harm.
Why it matters
Potential benefit: If successful, this approach could lead to safer cancer treatments and improved quality of life for patients undergoing immunotherapy.
How similar studies have gone: Other studies have shown promise in using digital tools for patient monitoring, but this specific approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Above 18 years of age * Cancer diagnosis as primary or secondary diagnosis according to the ICD-10 classification * Receiving immunotherapy as systemic anticancer treatment reported with ATC codes for medications. Exclusion Criteria: * Hematological cancer * Gynecological cancer
Where it's running
-
Nordlandssykehuset HF
Bodø, Nordland, Norway Recruiting
Study contacts
- Study coordinator: Ellinor C Haukland, MD, Phd
- Email: ellinor.haukland@nlsh.no
- Phone: +4792267328
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fixation methods for ankle fractures with posterior malleolus involvement
This study is testing a new way to fix certain ankle fractures to see if it works better than the usual methods for people with these types of injuries.
-
Using a carbohydrate-rich diet to treat acute intermittent porphyria
This study is testing whether a high-carbohydrate diet can help people with acute intermittent porphyria feel better by looking at changes in their symptoms and health markers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.